KEGG   DRUG: NatalizumabHelp
Entry
D06886                      Drug                                   

Name
Natalizumab (INN);
Natalizumab (genetical recombination) (JAN);
Tysabri (TN)
Product
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGASVKV SCKASGFNIK DTYIHWVRQA PGQRLEWMGR IDPANGYTKY
DPKFQGRVTI TADTSASTAY MELSSLRSED TAVYYCAREG YYGNYGVYAM DYWGQGTLVT
VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL
QSSGLYSLSS VVTVPSSSLG TKTYTCNVDH KPSNTKVDKR VESKYGPPCP SCPAPEFLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SRLTVDKSRW
QEGNVFSCSV MHEALHNHYT QKSLSLSLGK
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCKTSQDIN KYMAWYQQTP GKAPRLLIHY TSALQPGIPS
RFSGSGSGRD YTFTISSLQP EDIATYYCLQ YDNLWTFGQG TKVEIKRTVA APSVFIFPPS
DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
(dimer; dishulfide bridge: H22-H96, H137-L213, H150-H206, H229-H'229, H232-H'232, H264-H324, H370-H428, H'22-H'96, H'137-L'213, H'150-H'206, H'264-H'324, H'370-H'428, L23-L-88, L133-L193, L'23-L'88, L'133-L'193)
  Type
Peptide
Remark
Therapeutic category: 
ATC code: 
Chemical group: 
Efficacy
Immunosuppressant, Anti-integrin alpha 4 antibody
  Disease
Multiple sclerosis [DS:H01490]
Crohn's disease [DS:H00286]
Target
ITGA4 (CD49D) [HSA:3676] [KO:K06483]
  Pathway
Focal adhesion
ECM-receptor interaction
Cell adhesion molecules (CAMs)
Leukocyte transendothelial migration
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AA Selective immunosuppressants
     L04AA23 Natalizumab
      D06886  Natalizumab (INN)
USP drug classification [BR:br08302]
 Central Nervous System Agents
  Multiple Sclerosis Agents
   Natalizumab
    D06886  Natalizumab (INN)
 Immunological Agents
  Immunomodulators
   Natalizumab
    D06886  Natalizumab (INN)
Therapeutic category of drugs in Japan [BR:br08301]
 1  Agents affecting nervous system and sensory organs
  11  Agents affecting central nervous system
   119  Miscellaneous
    1190  Miscellaneous
     D06886  Natalizumab (INN); Natalizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Others
  Cellular antigens
   CD49d
    Natalizumab
     D06886  Natalizumab (INN)
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D06886
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D06886
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D06886
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D06886
BRITE hierarchy
Other DBs
CAS: 
189261-10-7
PubChem: 
DrugBank: 
NIKKAJI: 
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system